Spectrum, prevalence, and clinical correlates of <i>PPM1D</i> mutations in patients with clonal hematopoiesis and clonal cytopenias
Talha Badar(Mayo Clinic in Florida), Mrinal M. Patnaik(Mayo Clinic), Terra L. Lasho(Mayo Clinic), Aref Al‐Kali(Mayo Clinic), Abhishek A. Mangaonkar(Mayo Clinic), Mohamed A. Kharfan‐Dabaja(Jacksonville College), Francyess Denis Oliva(Duke University), Ludovica Marando(Wellcome/MRC Cambridge Stem Cell Institute), Omer Jamy(University of Alabama at Birmingham Hospital), James M. Foran(Memorial Sloan Kettering Cancer Center), Anand Patel(Ascension), Kendall Diebold(University of Alabama at Birmingham), Liuyan Jiang(Jacksonville College), Kristina Kirschner(Mayo Clinic), Maleeha Shah(Mayo Clinic), Benjamin J. McCormick(Jacksonville College), Yael Kusne(WinnMed), Chenyu Lin(Duke University), Alexander Coltoff(Columbia University Irving Medical Center), Christy M. Finke(Mayo Clinic), Rong He(Mayo Clinic), Mark R. Litzow(Mayo Clinic in Arizona), Kashish Shah(Jacksonville College), M. Thomas(University of Chicago), Mobachir El Kettani(Jacksonville College), Eric Latorre-Crespo(Centre de Recerca Matemàtica), Yao‐Shan Fan(Jacksonville College), D. Viswanatha(Mayo Clinic), Naseema Gangat(Mayo Clinic), Antoine N. Saliba(Mayo Clinic in Arizona)
Cited by 4
Related Papers
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Anthracycline Dose Intensification in Acute Myeloid Leukemia
|New England Journal of Medicine|2009|907